News
Xeljanz Gets FDA Committee Nod for Ulcerative Colitis Indication
The GIDAC recommendations are provided to the FDA but they are not binding. The FDA has set a target PDUFA action date of June 2018.
Your search for tofacitinib returned 11 results
News
Arthritis Drug May Help Eczema Patients, Too
A drug used to treat rheumatoid arthritis (RA) was effective in patients with moderate to severe eczema, according to a study conducted by researchers from Yale School of Medicine.
ACR/ARHP 2016 Annual Meeting
Tofacitinib Effective in PsA Patients With Prior Inadequate Response
Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study
News
FDA Panel Recommends Approval of Tofacitinib for Psoriatic Arthritis
The supplemental New Drug Applications (sNDAs) contained data from Phase 3 trials involving patients with psoriatic arthritis, including safety analyses from the larger tofacitinib clinical development program.
News
Methotrexate Monotherapy, Combo Therapy Compared for RA
Researchers from the University of Calgary found moderate to high quality evidence that triple therapy with methotrexate + sulfasalazine + hydroxycholoroquine or combining methotrexate + most biologic disease-modifying antirheumatic drug (DMARDs) or tofacitinib demonstrated similar efficacy in controlling disease activity in methotrexate-naive patients or after an inadequate response to methotrexate.
News
New Once-Daily Tabs Approved for Moderate to Severe RA
Pfizer announced that the Food and Drug Administration (FDA) has approved Xeljanz XR (tofacitinib citrate) extended-release tablets for once-daily treatment of moderate to severe rheumatoid arthritis (RA) in patients who have had an inadequate response or intolerance to methotrexate (MTX).
News
Does Tocilizumab Raise CV Risk in RA Patients?
Tocilizumab is known to raise LDL cholesterol levels but it is unclear whether the drug raises CV risk in RA patients.
News
Review: Biologic Monotherapy Compared to Traditional DMARDs for RA
The analysis focused on comparing the benefits and risks of biologic monotherapy, non-TNF agents, or tofacitinib monotherapy vs. placebo or methotrexate/other DMARDs.
News
Xeljanz Released from REMS Requirement
The FDA has approved a supplemental New Drug Application (sNDA) for Xeljanz (tofacitinib; Pfizer) to eliminate the requirement for the approved Risk Evaluation and Mitigation Strategy (REMS) assessment.
EULAR 2017
Tofacitinib Goes Head-to-Head with Adalimumab in Rheumatoid Arthritis Study
Xeljanz and Xeljanz XR are Janus kinase (JAK) inhibitors indicated to treat moderately to severely active rheumatoid arthritis when methotrexate therapy is inadequate.
